TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 27.55

Change

-0.69 (-2.44)%

Market Cap

USD 1.03B

Volume

0.86M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 115.81B
MRNA Moderna Inc

N/A

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.46B
ARGX argenx NV ADR

N/A

USD 26.22B
BNTX BioNTech SE

N/A

USD 18.98B
GMAB Genmab AS

N/A

USD 15.80B
RPRX Royalty Pharma Plc

N/A

USD 15.75B
BGNE BeiGene Ltd

N/A

USD 15.73B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.63B

ETFs Containing TARS

SLX VanEck Steel ETF 4.55 % 0.56 %

N/A

USD 0.09B
PYZ Invesco DWA Basic Materia.. 3.86 % 0.60 %

N/A

USD 0.06B
IJK iShares S&P Mid-Cap 400 G.. 1.24 % 0.24 %

N/A

USD 9.54B
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.16 % 0.15 %

N/A

USD 2.46B
ONEO SPDR® Russell 1000 Momen.. 0.68 % 0.20 %

N/A

USD 0.15B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.65 % 0.24 %

N/A

USD 21.41B
SPY4:LSE SSgA SPDR ETFs Europe I P.. 0.65 % 0.00 %

+0.14 (+0.16%)

USD 1.94B
IJH iShares Core S&P Mid-Cap .. 0.64 % 0.07 %

N/A

USD 82.98B
SPMD SPDR Russell Small Cap Co.. 0.61 % 0.06 %

N/A

USD 9.95B
VBR Vanguard Small-Cap Value .. 0.54 % 0.07 %

N/A

USD 28.05B
MVV ProShares Ultra MidCap400 0.48 % 0.95 %

N/A

USD 0.13B
MIDU Direxion Daily Mid Cap Bu.. 0.43 % 1.10 %

N/A

USD 0.07B
UMDD ProShares UltraPro MidCap.. 0.43 % 0.95 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.05% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.05% 83% B 89% A-
Trailing 12 Months  
Capital Gain 59.25% 88% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.25% 88% B+ 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.42% 62% D 55% F
Dividend Return 3.42% 61% D- 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.30% 55% F 33% F
Risk Adjusted Return 6.66% 65% D 45% F
Market Capitalization 1.03B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector